MedTrace Logo

Meloxicam in Mohs Micrographic Surgery

NCT07200544 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2025-12-15

No results posted yet for this study

Summary

The goal of this clinical trial is to explore alternative methods of postoperative pain control in Mohs micrographic surgery. The main aims are:

* To provide more information to the Mohs surgery community regarding postoperative pain control.
* Reducing pain improves the overall comfort and well-being of patients, leading to a better post-operative experience.
* To provide patients with an alternative and potentially superior NSAID for pain control (compared to standard-of-care ibuprofen).

Researchers will compare 1) a single of dose Meloxicam 7.5 mg, followed by acetaminophen 500 mg; 2) a single dose of Meloxicam 15 mg, followed by acetaminophen 500 mg; 3) a single dose of acetaminophen 500 mg, followed by alternating ibuprofen 200 mg and acetaminophen 500 mg to see which better moderate pain control and patient satisfaction.

Participants will be asked to complete pain and patient satisfaction surveys.

Conditions

Interventions

DRUG

Meloxicam 7.5 mg

This intervention is the mandatory oral Meloxicam 7.5mg dose after Mohs closure.

DRUG

Meloxicam 15 mg

This intervention is the mandatory oral Meloxicam 15mg dose after Mohs closure.

DRUG

Acetaminophen 500mg

This randomized control group will take a mandatory one-time dose of 500 mg acetaminophen with alternating 200 mg ibuprofen and 500 mg acetaminophen (standard of care) every 3 hours for pain.

Sponsors & Collaborators

  • University of Oklahoma

    lead OTHER

Principal Investigators

  • Lindsey Collins, MD · University of Oklahoma, Department of Dermatology

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
110 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-15
Primary Completion
2026-06-02
Completion
2026-08-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07200544 on ClinicalTrials.gov